The Protective Effects of 2'-Fucosyllactose against E. Coli O157 Infection Are Mediated by the Regulation of Gut Microbiota and the Inhibition of Pathogen Adhesion

Nutrients. 2020 May 1;12(5):1284. doi: 10.3390/nu12051284.

Abstract

As the richest component in human milk oligosaccharides (HMOs), 2'-fucosyllactose (2'-FL) can reduce the colonization of harmful microbiota in vivo, thus lowering the risk of infection; however, the mechanism for this is still unclear. In this study, a model of Escherichia coli O157 infection in healthy adult mice was established to explore the effect of 2'-FL intervention on E. coli O157 colonization and its protective effects on mice. The results showed that 2'-FL intake reduced E. coli O157 colonization in mice intestine by more than 90% (p < 0.001), and it also reduced intestinal inflammation, increased the content of fecal short-chain fatty acids, and enhanced intestinal barrier function. These beneficial effects were attributed to the increased expression of mucins such as MUC2 (increased by more than 20%, p < 0.001), and inhibition of E. coli O157 cell adhesion (about 30% reduction, p < 0.001), and were associated with the modulation of gut microbiota composition. 2'-FL significantly increased the abundance of Akkermansia, a potential probiotic, which may represent the fundamental means by which 2'-FL enhances the expression of mucin and reduces the colonization of harmful bacteria. The current study may support the use of 2'-FL in the prevention of foodborne pathogen infections in human.

Keywords: 2’-fucosyllactose; Akkermansia; E. coli O157; gut microbiota; reduced colonization.

MeSH terms

  • Animals
  • Bacterial Adhesion / drug effects*
  • Disease Models, Animal
  • Escherichia coli Infections*
  • Escherichia coli O157 / pathogenicity*
  • Escherichia coli O157 / physiology
  • Fatty Acids, Volatile / metabolism
  • Gastroenteritis / microbiology*
  • Gastroenteritis / prevention & control*
  • Gastrointestinal Microbiome / drug effects*
  • Inflammation / prevention & control
  • Intestinal Mucosa / metabolism*
  • Intestinal Mucosa / microbiology*
  • Male
  • Mice
  • Mucins / metabolism
  • Probiotics
  • Trisaccharides / pharmacology*
  • Trisaccharides / therapeutic use*

Substances

  • Fatty Acids, Volatile
  • Mucins
  • Trisaccharides
  • 2'-fucosyllactose